1. Scrip
  2. >>Business

Evotec CSO: BMS Opt In On CNS Compound ‘Augurs Well’ For Discovery Pact

Brings Bristol Myers Additional Program Rights In Neurodegenerative Diseases.

 
• By Sten Stovall

Further promising compounds will be explored after Bristol Myers Squibb exercised its option to enter an exclusive license for Evotec’s investigational EVT8683, generated by the German group’s iPSC platform as a potential treatment for neurodegenerative conditions.

EVT8683 is the CNS discovery alliance’s most advanced program • Source: Alamy

It took less than five years for a CNS drug discovery pact between Evotec SE and Bristol Myers Squibb Company using the German pharma’s novel iPSC platform to bring its first compound to the verge of clinical testing in humans, and further candidates are likely to emerge shortly from the alliance.

That was the message from Cord Dohrmann, Evotec’s chief science officer after news last week that BMS had exercised its option to enter into worldwide license for Evotec’s EVT8683, a clinical trial-ready small molecule targeting a key cellular stress

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.